Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04793958 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 61 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Completion pushed from Jul 31, 2026 to Oct 23, 2026
  2. Start date: Jul 19, 2021 to Jun 24, 2021v60
  3. Primary completion date changed from estimate of Jan 30, 2026 to Jan 16, 2026 Completion date: Jan 30, 2026 to Jul 31, 2026 · Start date: Jun 24, 2021 to Jul 19, 2021v59 Show 2 more changesShow less
    • Completion date: Jan 30, 2026 to Jul 31, 2026
    • Start date: Jun 24, 2021 to Jul 19, 2021
  4. Study sites: 385 to 419 Start date: Aug 3, 2021 to Jun 24, 2021v58 Show 1 more changeShow less
    • Start date: Aug 3, 2021 to Jun 24, 2021
  5. Primary completion date: Feb 28, 2025 to Jan 30, 2026 Start date: Jun 24, 2021 to Aug 3, 2021 · Completion date: Feb 28, 2026 to Jan 30, 2026v57 Show 2 more changesShow less
    • Start date: Jun 24, 2021 to Aug 3, 2021
    • Completion date: Feb 28, 2026 to Jan 30, 2026
Show 45 earlier versionsHide 45 earlier versions
  1. Start date: Mar 15, 2021 to Jun 24, 2021 Study sites: 283 to 385v56 Show 1 more changeShow less
    • Study sites: 283 to 385
  2. Study sites: 309 to 283v55
  3. Re-verified, no change to tracked fieldsv54
  4. Primary completion date: Apr 30, 2024 to Feb 28, 2025 Completion date: Dec 30, 2024 to Feb 28, 2026v53 Show 1 more changeShow less
    • Completion date: Dec 30, 2024 to Feb 28, 2026
  5. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 420 to confirmed 461 · Study sites: 314 to 309v52 Show 2 more changesShow less
    • Enrollment target: estimated 420 to confirmed 461
    • Study sites: 314 to 309
  6. Study sites: 313 to 314v51
  7. Study sites: 308 to 313v50
  8. Study sites: 306 to 308v49
  9. Study sites: 303 to 306v48
  10. Study sites: 302 to 303v47
  11. Study sites: 301 to 302v46
  12. Study sites: 300 to 301v45
  13. Study sites: 287 to 300v44
  14. Study sites: 280 to 287v43
  15. Study sites: 272 to 280v42
  16. Primary completion date: Sep 30, 2023 to Apr 30, 2024v41
  17. Study sites: 244 to 272v40
  18. Study sites: 242 to 244v39
  19. Study sites: 238 to 242v38
  20. Study sites: 237 to 238v37
  21. Study sites: 235 to 237v36
  22. Study sites: 232 to 235v35
  23. Study sites: 224 to 232v34
  24. Study sites: 220 to 224v33
  25. Study sites: 214 to 220v32
  26. Study sites: 209 to 214v31
  27. Study sites: 204 to 209v30
  28. Study sites: 189 to 204v29
  29. Study sites: 141 to 189v28
  30. Study sites: 132 to 141v27
  31. Study sites: 117 to 132v26
  32. Study sites: 111 to 117v25
  33. Study sites: 97 to 111v24
  34. Study sites: 83 to 97v23
  35. Study sites: 78 to 83v22
  36. Study sites: 66 to 78v21
  37. Re-verified, no change to tracked fieldsv20
  38. Study sites: 61 to 66v19
  39. Study sites: 58 to 61v18
  40. Study sites: 51 to 58v17
  41. Study sites: 50 to 51v16
  42. Study sites: 45 to 50v15
  43. Study sites: 42 to 45v14
  44. Re-verified, no change to tracked fieldsv13
  45. Study sites: 31 to 42v12
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Trial Details
NCT Number NCT04793958
Lead Sponsor Mirati Therapeutics Inc.
Conditions Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Enrollment 461 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov